DOACs Useful Alternative for Treating Cancer-Associated VTE DOACs Useful Alternative for Treating Cancer-Associated VTE
Direct oral anticoagulants (DOACs) can be a safe alternative to low-molecular-weight heparin (LMWH) for treating cancer-associated venous thromboembolism (VTE), according to a new review.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 18, 2019 Category: Intensive Care Tags: Hematology-Oncology News Source Type: news

Conformal Medical launches LAA seal study
Conformal Medical said yesterday that it launched an investigational device exemption trial for a device designed to seal off the heart’s left atrial appendage to help prevent stroke in atrial fibrillation patients. Nashua, N.H.-based Conformal’s device is designed to adapt to the each patient’s individual physiology, to be easier to implant with less imaging and without general anesthesia. The 45-patient, single-arm study is designed to evaluate the device’s performance, with an estimated primary completion date of April 2020 and a final completion date of June 2025, according to ClinicalTrials.gov...
Source: Mass Device - April 10, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Implants Clinical Trials Featured Conformal Medical Source Type: news

PFO Requirements; Catheter Coating Emboli; BASILICA for Leaflet Thrombosis
(MedPage Today) -- Interventional cardiology news to note (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 21, 2019 Category: American Health Source Type: news

Direct Oral Anticoagulants of Benefit in Afib With Mitral Stenosis (CME/CE)
(MedPage Today) -- DOACs linked with lower rates of thromboembolism than warfarin and just as effective in preventing hemorrhagic strokes (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - March 17, 2019 Category: Urology & Nephrology Source Type: news

Cochrane in Everyday Life - Compression stockings for preventing deep vein thrombosis in airline passengers
Conclusions:High ‐quality evidence shows that airline passengers similar to those in the trials in this review can expect a substantial reduction in their risk of a symptomless deep vein thrombosis (DVT) if they wear compression stockings. Wearing stockings might reduce the incidence of this outcome from a few ten s per thousand passengers, to two or three per thousand. There is moderate‐quality evidence that superficial vein thrombosis may be reduced if passengers wear compression stockings. Low‐quality evidence shows that passengers who wear stockings will also experience less oedema in their legs. Howe ver, this r...
Source: Cochrane News and Events - March 14, 2019 Category: Information Technology Authors: Muriah Umoquit Source Type: news

CASSINI Trial Assesses Rivaroxaban for Thromboprophylaxis in Cancer Patients
In a phase IIIb trial, researchers evaluated the efficacy of an oral anticoagulant in cancer patients  at high risk for venous thromboembolism. (Source: CancerNetwork)
Source: CancerNetwork - March 13, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

The Thomas C Chalmers Award - 2018 Award Winner, Adriani Nikolakopoulou
TheThomas C Chalmers Award is awarded to the principal author of the best oral and the best poster presentation addressing methodological issues related to systematic reviews.Tom Chalmers (1917-1995) was an outspoken advocate of randomised trials, whether at the bedside, at professional meetings, in class or in situations pertaining to his own life. His creativity spanned his entire career, influencing clinicians and methodologists alike. He is perhaps best known for the notion ‘randomise the first patient’, his belief that it is more ethical to randomise patients than to treat them in the absence of good evide...
Source: Cochrane News and Events - March 12, 2019 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Endogenous Testosterone Tied to Higher Heart Disease Risks (CME/CE)
(MedPage Today) -- Endogenous testosterone could be a modifiable risk factor for thromboembolism and heart failure (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 11, 2019 Category: Cardiology Source Type: news

Jax drug developer lands favored FDA status, paving way for next step in clinical trails
Jacksonville-based Espero BioPharma Inc. has received an FDA designation for its blood thinner that will grant it a waiver from FDA fees and tax credits for clinical research. Espero's tecarfarin, a drug to prevent systemic thromboembolism in patients with end stage renal disease and atrial fibrillation, was granted the FDA's Orphan Drug Designation, the company announced Monday. The drug is is ready for phase 3 clinical testing, in which it will evaluated for one to fo ur years with 300 to 3,000… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 11, 2019 Category: Pharmaceuticals Authors: Will Robinson Source Type: news

Endogenous Testosterone Linked to Cardiovascular Disease
THURSDAY, March 7, 2019 -- In men, endogenous testosterone may have a causal role in thromboembolism, heart failure, and myocardial infarction, according to a study published online March 6 in The BMJ. Shan Luo, from the University of Hong Kong, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2019 Category: Pharmaceuticals Source Type: news

Marshall University researcher receives nearly $500,000 NIH grant for thrombosis research
(Marshall University Joan C. Edwards School of Medicine) Wei Li, M.D., Ph.D., an associate professor in the department of biomedical science at the Marshall University Joan C. Edwards School of Medicine was recently awarded a grant from the National Institutes of Health to further his research on thrombosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 7, 2019 Category: International Medicine & Public Health Source Type: news

Ultrasound for thrombosis prevention
(Moscow Institute of Physics and Technology) Researchers established real-time ultrasonic monitoring of the blood's aggregate state using the in vitro blood flow model. Based on collected data, computer automatically injected a thrombolytic drug if needed. As a result, the system was able to quickly and completely dissolve the forming blood clots. The team believes that their work will help open new prospects for the creation of wearable devices for timely medical assistance to patients with a high risk of thrombosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 6, 2019 Category: International Medicine & Public Health Source Type: news

Lotus, CoreValve On Par for Survival, Stroke Longer Term
(MedPage Today) -- But pacemaker rate, hemodynamics, valve thrombosis raise concerns (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 1, 2019 Category: Cardiology Source Type: news

The Thomas C Chalmers Award - 2018 Award Winner, Leonie Van Grootel
TheThomas C Chalmers Award is awarded to the principal author of the best oral and the best poster presentation addressing methodological issues related to systematic reviews.Tom Chalmers (1917-1995) was an outspoken advocate of randomised trials, whether at the bedside, at professional meetings, in class or in situations pertaining to his own life. His creativity spanned his entire career, influencing clinicians and methodologists alike. He is perhaps best known for the notion ‘randomise the first patient’, his belief that it is more ethical to randomise patients than to treat them in the absence of good evide...
Source: Cochrane News and Events - March 1, 2019 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Bayer Thrombosis Research Award 2019 goes to Dr. Changjun Yin
The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 prize to Dr. Changjun Yin from the Institute for Cardiovascular Prevention at the Ludwig-Maximilians-University in Munich in recognition of his research on Atherosclerosis and Alzheimer's disease (AD) as inflammatory conditions with high risks to develop thrombosis-related diseases. (Source: World Pharma News)
Source: World Pharma News - February 28, 2019 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Study of Boston Scientific ’s Lotus, Medtronic’s CoreValve shows similar outcomes at 2 years
Two-year results from a head-to-head study comparing transcatheter aortic heart valve replacement devices from both Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) indicated similar outcomes for the competing products. The study, published recently in the journal JAMA Cardiology, compared Marlborough, Mass.-based Boston Scientific’s Lotus valve to Fridley, Minn.-based Medtronic’s CoreValve system. Investigators in the study compared outcomes for 912 patients with high or extreme risk and severe, symptomatic aortic stenosis after treatment with one of the two devices. Patients, treated between Se...
Source: Mass Device - February 28, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Featured Replacement Heart Valves Boston Scientific Medtronic Source Type: news

Hypercoagulation After Cardiac Arrest
Optimal intra- and post-arrest care for out-of-hospital cardiac arrest (OHCA) requires careful management of the complex interaction between clot formation (i.e., coagulation) and its natural resolution (i.e., fibrinolysis).1 In greater than 70% of cases, OHCA is caused by a clot blocking either a coronary artery, pulmonary artery, acute coronary syndrome (ACS), or pulmonary thromboembolism (PTE).2 When OHCA occurs, lack of pulsatile blood flow facilitates rapid clot formation in larger blood vessels and structures demonstrated by abnormally high levels of clotting byproducts, such as d-dimer.3 CPR mechanically disrupts fu...
Source: JEMS Patient Care - February 27, 2019 Category: Emergency Medicine Authors: Michael C. Kurz, MD, MS-HES, FACEP Tags: Cardiac & Resuscitation Top Story Exclusive Articles Patient Care Heart of America Source Type: news

Medtronic Keeps DES Market Hot with New Indication
Rumblings in the Drug-Eluting Stent market continued this week after Medtronic said it has obtained FDA approval for an additional indication for its Resolute DES platform and the Resolute Integrity. The Dublin-based company’s new indication is for the treatment of patients with coronary disease who have de novo chronic total occlusion (CTO), a complex vessel condition involving complete blockage of a coronary artery. CTO is considered more difficult to treat with percutaneous coronary intervention (PCI) due to a greater risk of complications. The expanded CTO indication was supported by data from the PER...
Source: MDDI - February 26, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

VTE Prophylaxis for High-Risk Ambulatory Cancer Patients? VTE Prophylaxis for High-Risk Ambulatory Cancer Patients?
Two studies showed a benefit for direct oral anticoagulants for the prevention of venous thromboembolism in high-risk ambulatory cancer patients, but will this change clinical practice?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 25, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biotronik Has a New DES Added to its Repertoire
FDA has just signed off on Biotronik’s Orsiro drug-eluting stent (System). The Lake Oswego, OR-based company claims the stent is the first and ultrathin DES to outperform Abbott Laboratories’, Xience stent, which is known as the clinical standard. Biotronik said its first implants will occur this week and that it will be available in health systems in the early part of this year. The company has had CE mark for Orsiro since 2011. Perhaps the biggest selling point of the technology is the ultrathin strut design. “Thinner struts are different in that they potentially crea...
Source: MDDI - February 25, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

Rivaroxaban Does Not Reduce VTE Incidence in High-Risk Cancer Patients
THURSDAY, Feb. 21, 2019 -- In high-risk ambulatory patients with cancer, the incidence of venous thromboembolism or death due to venous thromboembolism during 180 days is not significantly reduced for rivaroxaban compared with placebo, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 21, 2019 Category: Pharmaceuticals Source Type: news

Hormone Therapy Linked to CV Risk During Gender Transition Hormone Therapy Linked to CV Risk During Gender Transition
Transgender hormone therapy is associated with an increased risk for MI, stroke, and venous thromboembolism, underscoring the importance of patient counseling and close monitoring in this population.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

CASSINI Trial publishes data on preventing blood clots in cancer patients
(Fred Hutchinson Cancer Research Center) The first clinical study investigating the use of the direct oral anticoagulant, rivaroxaban, to prevent blood clots in patients with cancer at high-risk published today in the New England Journal of Medicine. The study found no significant reduction in venous thromboembolism or death in the overall 180-day trial period; however, the researchers did observe a lower incidence of these events while patients were actively on the study drug, or during the on-treatment period. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2019 Category: Cancer & Oncology Source Type: news

Hancock Jaffe launches first-in-human VenoValve study
Hancock Jaffe Laboratories (NSDQ:HJLI) said today that it launched the first-in-human study of its VenoValve device, touting its successful implantation in the first subject in the study. The VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves after deep vein thrombosis, the Irvine, Calif.-based company said. Hancock Jaffe said that the first patient in the Bogota, Colombia-based trial was walking a day after surgery and that the VenoValve appears to “be functioning as it should” w...
Source: Mass Device - February 19, 2019 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Featured Vascular hancockjaffelabs Source Type: news

PET/CT imaging agent shows promise for better diagnosis of acute venous thromboembolism
(Society of Nuclear Medicine and Molecular Imaging) Researchers report that a new nuclear medicine tracer may allow better diagnosis of acute venous thromboembolism (VTE). Acute VTE is a disease that includes deep-vein thrombosis and its complication, pulmonary embolism, which can be fatal. The research is featured in the February issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 15, 2019 Category: International Medicine & Public Health Source Type: news

VTE Risk High in Spine Disease
(MedPage Today) -- More deep venous thrombosis than pulmonary embolism seen in ankylosing spondylitis (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - February 14, 2019 Category: Rheumatology Source Type: news

Platelet doppelg ä ngers tackle thrombosis and cancer metastasis
(American Association for the Advancement of Science) Anne-Laure Papa and colleagues have created decoys of platelets -- the body's clot-forming blood cells -- that prevented the formation of dangerous blood clots in vessels (or thrombosis) and combated cancer metastasis in preclinical models. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2019 Category: Cancer & Oncology Source Type: news

Risk of Thrombosis Over 2-Fold Higher in Male Breast Cancer With Tamoxifen (CME/CE)
(MedPage Today) -- Increased rate for men consistent with that found in women -- maybe higher (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 12, 2019 Category: Cardiology Source Type: news

Treatment Not Needed for DVT in Very Advanced Cancer Patients Treatment Not Needed for DVT in Very Advanced Cancer Patients
Deep vein thrombosis (DVT) is seen in about a third of patients with very advanced cancer, but its presence is not associated with significant symptoms or survival.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 12, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: What to know about a blood clot behind the knee
A blood clot can form behind the knee due to injuries, surgery, or poor blood flow. A clot forming in a leg vein is a serious condition that can lead to potentially life-threatening complications, such as a pulmonary embolism. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 8, 2019 Category: Consumer Health News Tags: Venous Thromboembolism (VTE) Source Type: news

Thoratec inks $12m investor suit settlement deal
Abbott (NYSE:ABT) owned Thoratec is seeking approval for a $11.9 million deal to settle class action claims that it and some of its officers hid facts about its Heartmate II heart pump’s thrombosis rate that would have negatively affected share prices, according to recently released court documents. Investor Bradley Cooper originally brought the suit against the company in January 2014, on behalf of anyone who bought stock between April 29, 2010, and Nov. 27, 2013. Plaintiffs in the case argued that the company failed to warn investors about a blood clot problem with its HeartMate II implant implicated in a...
Source: Mass Device - February 6, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiac Assist Devices Cardiovascular Legal News Abbott Thoratec Corp. Source Type: news

Thrombosis a Risk With Tamoxifen in Male Breast Cancer
(MedPage Today) -- Data consistent with findings in women (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 6, 2019 Category: Cardiology Source Type: news

Estrogen and Venous Thrombosis: Route, Type, and Dose Matter! Estrogen and Venous Thrombosis: Route, Type, and Dose Matter!
JoAnn Manson reviews a large study that provides evidence about the safety of different estrogen formulations for menopausal hormone therapy.Medscape Ob/Gyn (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2019 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Commentary Source Type: news

Products made from whole milk, not 2% "processed" milk, reduce risk of blood clots in the brain
(Natural News) A study published in the European Journal of Epidemiology reveals that soured whole milk products are more effective at reducing the risk of suffering from brain thrombosis or ischemic stroke compared with other dairy products — such as low-fat soured milk products and cheese, buttermilk, or milk — with varying fat percentages. A team of researchers at... (Source: NaturalNews.com)
Source: NaturalNews.com - January 27, 2019 Category: Consumer Health News Source Type: news

Endologix ’s CE Mark for Nellix is Suspended
It looks like more bad news for Endologix.  The Irvine, CA-based company said its CE Mark for the Nellix EndoVascular Aneurysm Sealing System has been suspended by its Notified Body, GMED. Endologix first received approval in Europe for the device in 2013. The Nellix system was developed as an alternative treatment to traditional endovascular aneurysm repair for an abdominal aortic aneurysm. The system is designed to seal an entire aneurysm. “The notification from GMED is a regulatory action and is not in response to any new information beyond our recent FSN,” Dr. Matt Thomps...
Source: MDDI - January 25, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Regulatory and Compliance Source Type: news

New SCCT Guidelines Reflect Expanding Role for CT in TAVR New SCCT Guidelines Reflect Expanding Role for CT in TAVR
It features nuts-and-bolts recommendations, including those for specific scanners, but also thorny issues like leaflet thrombosis and valve-in-valve procedures for failed bioprosthesis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 18, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Aspiration Thrombectomy in STEMI PCI Plummets Nationwide Aspiration Thrombectomy in STEMI PCI Plummets Nationwide
No benefits were found for thrombus aspiration, either routine or selective, but there remains an unmet need in high-risk patients undergoing PCI.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 16, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

What Are Potential Complications of Large for Gestational Birthweight?
Discussion Infant size at birth is determined mainly by genetics, but also pregnancy and environmental factors. Large for gestational age (LGA) is defined as a mean weight> 2 standard deviations above the weight for gestational age or above the 90th percentile on growth charts (or ~4000 g on WHO growth charts). Macrosomia is a term used for a term infant who is> 4000g. Risk factors for LGA infants includes: Male infant Maternal Genetic disposition Hispanic ethnicity Diabetic Multiparity or grand parity Obesity History of previous LGA infant Prenatal ultrasound is very helpful for antenatal management. First tri...
Source: PediatricEducation.org - January 14, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

A 55-Year-Old Woman Short of Breath: USMLE Question A 55-Year-Old Woman Short of Breath: USMLE Question
A 55-year-old woman presents with shortness of breath. She has a history of deep vein thrombosis and current breast cancer. What's the next step in management?Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 11, 2019 Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news

Oral HRT for Menopause Has Highest VTE Risk, Dermal Route Safest Oral HRT for Menopause Has Highest VTE Risk, Dermal Route Safest
Women taking HRT for menopausal symptoms should be counseled to use transdermal preparations over oral ones to reduce their venous thromboembolism risk, conclude UK experts following large study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2019 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Oral HRT for Menopause Has Highest VTE Risk, Patches Safest Oral HRT for Menopause Has Highest VTE Risk, Patches Safest
Women taking HRT for menopausal symptoms should be counseled to use transdermal preparations over oral ones to reduce their venous thromboembolism risk, conclude UK experts following large study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2019 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Transdermal HRT Not Linked to Increased Risk for VTE
THURSDAY, Jan. 10, 2019 -- Oral hormone replacement therapy (HRT) is associated with an increased risk for venous thromboembolism (VTE), while transdermal preparations are not linked to increased risk, according to a study published online Jan. 9 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 10, 2019 Category: Pharmaceuticals Source Type: news

Hancock Jaffe sets endpoints for FIH VenoValve study
Hancock Jaffe Laboratories (NSDQ:HJLI) today announced the endpoints for its planned first-in-human study of its VenoValve device. The VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves after deep vein thrombosis, the Irvine, Calif.-based company said. Endpoints for the study include improvements in reflux time measured by duplex scans and rVCSS, VAS and VEINES scores, which are used as clinical measurements for venous disease. Hancock Jaffe said that patients in the trial will be monitored at reg...
Source: Mass Device - January 9, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Replacement Heart Valves hancockjaffelabs Source Type: news

Medtech veteran Reggie Groves on leading with ‘patients first’
In guiding Medtronic through the Fidelis lead recall, medtech veteran Reggie Groves always took a “patients first” perspective. At DeviceTalks West 2018, Groves explained how her time at Medtronic influenced her as a leader and how she has brought those lessons into her role as CEO of Reva Medical. Once the world’s most popular defibrillator lead, Medtronic’s Fidelis leads were in hundreds of thousands of patients in the U.S. So when the device began delivering random, painful shocks to people about a decade ago, Medtronic officials were worried. That included Reggie Groves, who was charged with run...
Source: Mass Device - January 7, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Featured Recalls Vascular Wall Street Beat DeviceTalks West Medtronic Reva Medical Inc. Source Type: news

Endologix Voluntarily Recalls Nellix
Endologix said it was initiating a voluntary recall of the existing inventory of its Nellix endovascular aneurysm sealing system. The Irvine, CA-based company said it was limiting the device to only be available for use under clinical protocol with pre-screened patients that adhere to the current indications. Endologix said it was taking these steps in order to ensure optimal outcomes for patients. This decision is one of several actions taken by Endologix following a new management mandate in August 2018 to ensure the most appropriate use of each of its devices and is in alignment with a recent publication by the European...
Source: MDDI - January 6, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Regulatory and Compliance Source Type: news

New DVT Device Designed to Tackle Stubborn ‘Wall-to-Wall’ Clot
Vetex Medical recently completed the first-in-man case in a multicenter study of a new deep vein thrombosis (DVT) device that has the potential to reduce hospital stays and costs associated with DVT treatment. The Galway, Ireland-based company said the Vetex Thrombectomy Catheter is the first device to combine rotational and grasping action to quickly and gently remove large volumes of stubborn wall-adherent clot in a single session, without thrombolytic drugs. The first patient was treated by the study’s principal investigator Stephen Black, MD, Narayan Thulasidasan, MD, and their team at Guyâ€...
Source: MDDI - January 4, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: R & D Source Type: news

People leaving hospital after medical illness do not benefit from extended clot reducing treatment
Taking rivaroxaban after discharge from hospital does not significantly reduce the risk of venous thromboembolism, either blood clots in large veins or of dying from clots travelling to the lungs. This large multinational trial sought to find out whether using the anticoagulant rivaroxaban for 45 days after discharge was effective. Continued use offered a very small reduction in the risk of a venous thromboembolism, but also slightly increased the risk of major bleeding. Neither result reached statistical significance. The trial was terminated because of the lower than expected number of clots. (Source: Current Awareness S...
Source: Current Awareness Service for Health (CASH) - January 3, 2019 Category: Consumer Health News Source Type: news

Cities really are death traps: Sitting in traffic found to suppress HDL "good" cholesterol that prevents cardiovascular disease
(Natural News) Traffic-related air pollution is seen to manipulate the levels of high-density lipoprotein (HDL), otherwise known as “good” cholesterol. These are the findings of the American Heart Association (AHA) in their recent study published in Arteriosclerosis, Thrombosis, and Vascular Biology. These lowered levels are evident even after brief and medium-length exposures to air pollution.... (Source: NaturalNews.com)
Source: NaturalNews.com - December 28, 2018 Category: Consumer Health News Source Type: news

ASH Develops Practice Guidelines for Venous Thromboembolism
Clinical practice guidelines presented for diagnosis, treatment, pediatric and pregnancy - linked VTE (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 27, 2018 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Internal Medicine, Critical Care, Oncology, Pediatrics, Pharmacy, Surgery, Geriatrics, Journal, Source Type: news

MI, Stroke Risks Rise Months Before Cancer Diagnosis MI, Stroke Risks Rise Months Before Cancer Diagnosis
About 5 months before a cancer diagnosis, the risk for arterial thromboembolism increases and continues to climb as the diagnosis date draws closer.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 27, 2018 Category: Cardiology Tags: Hematology-Oncology News Source Type: news